KIAA1429 increases FOXM1 expression through YTHDF1–mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma
Authors:
Open Access
- 26 July 2024
- journal article
- research article
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 40 (1) , 1-17
Abstract
Objective: Multiple myeloma (MM) is a deadly plasma cell malignancy with elusive pathogenesis. N6-methyladenosine (m6A) is critically engaged in hematological malignancies. The function of KIAA1429, the largest component of methyltransferases, is unknown. This study delved into the mechanism of KIAA1429 in MM, hoping to offer novel targets for MM therapy. Methods: Bone marrow samples were attained from 55 MM patients and 15 controls. KIAA1429, YTHDF1, and FOXM1 mRNA levels were detected and their correlation was analyzed. Cell viability, proliferation, cell cycle, and apoptosis were testified. Glycolysis-enhancing genes (HK2, ENO1, and LDHA), lactate production, and glucose uptake were evaluated. The interaction between FOXM1 mRNA and YTHDF1, m6A-modified FOXM1 level, and FOXM1 stability were assayed. A transplantation tumor model was built to confirm the mechanism of KIAA1429. Results: KIAA1429 was at high levels in MM patients and MM cells and linked to poor prognoses. KIAA1429 knockdown restrained MM cell viability, and proliferation, arrested G0/G1 phase, and increased apoptosis. KIAA1429 mRNA in plasma cells from MM patients was positively linked with to glycolysis-enhancing genes. The levels of glycolysis-enhancing genes, glucose uptake, and lactate production were repressed after KIAA1429 knockdown, along with reduced FOXM1 levels and stability. YTHDF1 recognized KIAA1429-methylated FOXM1 mRNA and raised FOXM1 stability. Knockdown of YTHDF1 curbed aerobic glycolysis and malignant behaviors in MM cells, which was nullified by FOXM1 overexpression. KIAA1429 knockdown also inhibited tumor growth in animal experiments. Conclusion: KIAA1429 knockdown reduces FOXM1 expression through YTHDF1-mediated m6A modification, thus inhibiting MM aerobic glycolysis and tumorigenesis. Graphical KIAA1429 knockdown reduces FOXM1 expression through YTHDF1-mediated m6A modification, thus inhibiting aerobic glycolysis and tumorigenesis in MMKeywords
This publication has 48 references indexed in Scilit:
- N6-methyladenosine (m6A) writer KIAA1429 accelerates gastric cancer oxaliplatin chemoresistance by targeting FOXM1Journal of Cancer Research and Clinical Oncology, 2022
- N6‐methyladenosine regulators are potential prognostic biomarkers for multiple myelomaIUBMB Life, 2022
- Gene amplification‐driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A‐YTHDF2‐dependent in lung adenocarcinomaCancer Communications, 2022
- METTL3 facilitates multiple myeloma tumorigenesis by enhancing YY1 stability and pri-microRNA-27 maturation in m6A-dependent mannerCell Biology and Toxicology, 2022
- m6A transferase KIAA1429‐stabilized LINC00958 accelerates gastric cancer aerobic glycolysis through targeting GLUT1IUBMB Life, 2021
- Multiple myeloma: Every year a new standard?Hematological Oncology, 2019
- Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management StrategiesCurrent Hematologic Malignancy Reports, 2018
- Dynamic RNA Modifications in Gene Expression RegulationCell, 2017
- Nuclear m6A Reader YTHDC1 Regulates mRNA SplicingMolecular Cell, 2016
- N6-methyladenosine Modulates Messenger RNA Translation EfficiencyCell, 2015